Literature DB >> 35286706

The Immunogenetics of Cutaneous Drug Reactions.

Neda Khalili1.   

Abstract

Adverse drug reactions (ADRs) are the cause of nearly three to six percent of inpatient admissions and are associated with high morbidity and mortality rates. Cutaneous adverse drug reactions (cADRs) represent the most frequent ADRs observed among patients during hospital stay. Recent investigations have found that various HLA genotypes have a significant association with ADRs, especially immune-mediated ADRs. This chapter is devoted to the description of the immunopathogenic mechanism of these reactions and the specific HLA-drug associations. Also, we discuss the association of other non-HLA genes with the development of cADRs and provide a summary of the currently approved recommendations on pre-treatment HLA genotyping tests.
© 2022. Springer Nature Switzerland AG.

Entities:  

Keywords:  Adverse drug reactions; Cutaneous adverse drug reaction; Genotyping; HLA antigens

Mesh:

Year:  2022        PMID: 35286706     DOI: 10.1007/978-3-030-92616-8_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  136 in total

1.  Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies.

Authors:  H J M Beijer; C J de Blaey
Journal:  Pharm World Sci       Date:  2002-04

Review 2.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

3.  Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria.

Authors:  Jin-Sik Bae; Seung-Hyun Kim; Young-Min Ye; Ho Joo Yoon; Chang-Hee Suh; Dong-Ho Nahm; Hae-Sim Park
Journal:  J Allergy Clin Immunol       Date:  2006-11-27       Impact factor: 10.793

4.  HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.

Authors:  Zhi-hao Cao; Zhi-yun Wei; Qin-yuan Zhu; Jun-yu Zhang; Lun Yang; Sheng-ying Qin; Li-yan Shao; Yi-ting Zhang; Jie-kun Xuan; Qiao-li Li; Jin-Hua Xu; Feng Xu; Li Ma; Hui-yuan Huang; Qing-he Xing; Xiao-qun Luo
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

5.  Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

Review 6.  Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.

Authors:  Ursula Amstutz; Neil H Shear; Michael J Rieder; Soomi Hwang; Vincent Fung; Hidefumi Nakamura; Mary B Connolly; Shinya Ito; Bruce C Carleton
Journal:  Epilepsia       Date:  2014-03-05       Impact factor: 5.864

7.  Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS).

Authors:  A Barbaud; J Waton; B Herbeth; A C Bursztejn; M Bollaert; J L Schmutz; R M Guéant-Rodriguez; F Namour; J L Guéant; I Aimone-Gastin
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-03-06       Impact factor: 6.166

Review 8.  CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Authors:  Luis H Camacho
Journal:  Cancer Med       Date:  2015-01-25       Impact factor: 4.452

Review 9.  Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.

Authors:  Ruwen Böhm; Ingolf Cascorbi
Journal:  Front Pharmacol       Date:  2016-10-21       Impact factor: 5.810

10.  Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.

Authors:  Daniel F Carr; Stephane Bourgeois; Mas Chaponda; Louise Y Takeshita; Andrew P Morris; Elena M Cornejo Castro; Ana Alfirevic; Andrew R Jones; Daniel J Rigden; Sam Haldenby; Saye Khoo; David G Lalloo; Robert S Heyderman; Collet Dandara; Elizabeth Kampira; Joep J van Oosterhout; Francis Ssali; Paula Munderi; Giuseppe Novelli; Paola Borgiani; Matthew R Nelson; Arthur Holden; Panos Deloukas; Munir Pirmohamed
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.